Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Not Yet Recruiting1
Active Not Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07349641Phase 2Not Yet RecruitingPrimary

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

NCT04576104Phase 2Active Not RecruitingPrimary

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

NCT03300557Phase 2Completed

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Showing all 3 trials

Research Network

Activity Timeline